PhaseBio Pharmaceuticals Inc

2020 Q1 Form 10-Q Financial Statement

#000116924520000051 Filed on May 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.40M $51.90M
YoY Change 14.45%
Cash & Equivalents $59.40M $51.91M
Short-Term Investments
Other Short-Term Assets $12.20M $1.500M
YoY Change 713.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables $896.0K $670.0K
Total Short-Term Assets $72.54M $54.08M
YoY Change 34.15%
LONG-TERM ASSETS
Property, Plant & Equipment $2.637M $380.0K
YoY Change 593.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $32.00K $32.00K
YoY Change 0.0%
Total Long-Term Assets $4.317M $2.311M
YoY Change 86.8%
TOTAL ASSETS
Total Short-Term Assets $72.54M $54.08M
Total Long-Term Assets $4.317M $2.311M
Total Assets $76.86M $56.39M
YoY Change 36.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.918M $2.100M
YoY Change -8.67%
Accrued Expenses $1.900M $1.300M
YoY Change 46.15%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.686M $400.0K
YoY Change 821.5%
Total Short-Term Liabilities $7.495M $3.800M
YoY Change 97.24%
LONG-TERM LIABILITIES
Long-Term Debt $11.06M $6.841M
YoY Change 61.64%
Other Long-Term Liabilities $295.0K $1.700M
YoY Change -82.65%
Total Long-Term Liabilities $11.35M $6.841M
YoY Change 65.96%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.495M $3.800M
Total Long-Term Liabilities $11.35M $6.841M
Total Liabilities $23.37M $12.30M
YoY Change 89.95%
SHAREHOLDERS EQUITY
Retained Earnings -$177.1M -$130.2M
YoY Change 35.99%
Common Stock $29.00K $25.00K
YoY Change 16.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $24.00K $24.00K
YoY Change 0.0%
Treasury Stock Shares 29.97K shares $29.97K
Shareholders Equity $53.49M $44.08M
YoY Change
Total Liabilities & Shareholders Equity $76.86M $56.39M
YoY Change 36.31%

Cashflow Statement

Concept 2020 Q1 2019 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001169245
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28781044 shares
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
PhaseBio Pharmaceuticals Inc
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q4 phas Accrued Clinical And Related Costs Current
AccruedClinicalAndRelatedCostsCurrent
819000 USD
CY2020Q1 phas Accrued Clinical And Related Costs Current
AccruedClinicalAndRelatedCostsCurrent
695000 USD
CY2019Q4 phas Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
3180000 USD
CY2020Q1 phas Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1891000 USD
CY2019Q1 phas Accrued Interest On Term Loan Refinanced To Principal
AccruedInterestOnTermLoanRefinancedToPrincipal
308000 USD
CY2020Q1 phas Accrued Interest On Term Loan Refinanced To Principal
AccruedInterestOnTermLoanRefinancedToPrincipal
0 USD
CY2020Q1 phas Aggregate Offering Price Of Common Stock Preferred Stock Debt Securities And Warrants
AggregateOfferingPriceOfCommonStockPreferredStockDebtSecuritiesAndWarrants
200000000 USD
CY2019Q1 phas Debt Refinanced With New Term Loan
DebtRefinancedWithNewTermLoan
6563000 USD
CY2020Q1 phas Debt Refinanced With New Term Loan
DebtRefinancedWithNewTermLoan
0 USD
CY2019Q1 phas Deferred Stock Offering Costs In Accounts Payable
DeferredStockOfferingCostsInAccountsPayable
0 USD
CY2020Q1 phas Deferred Stock Offering Costs In Accounts Payable
DeferredStockOfferingCostsInAccountsPayable
45000 USD
CY2019Q1 phas Gain Loss From Remeasurement Of Derivative Liability
GainLossFromRemeasurementOfDerivativeLiability
0 USD
CY2020Q1 phas Gain Loss From Remeasurement Of Derivative Liability
GainLossFromRemeasurementOfDerivativeLiability
-454000 USD
CY2019Q1 phas Initial Recognition Of Operating Lease Right Of Use Assets And Operating Lease Liabilities
InitialRecognitionOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilities
1991000 USD
CY2020Q1 phas Initial Recognition Of Operating Lease Right Of Use Assets And Operating Lease Liabilities
InitialRecognitionOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilities
0 USD
CY2019Q1 phas Issuanceof Stockand Warrantsfor Derivative Instruments
IssuanceofStockandWarrantsforDerivativeInstruments
0 USD
CY2020Q1 phas Issuanceof Stockand Warrantsfor Derivative Instruments
IssuanceofStockandWarrantsforDerivativeInstruments
7925000 USD
CY2019Q1 phas Noncashor Part Noncash Researchand Development Expense
NoncashorPartNoncashResearchandDevelopmentExpense
0 USD
CY2020Q1 phas Noncashor Part Noncash Researchand Development Expense
NoncashorPartNoncashResearchandDevelopmentExpense
557000 USD
CY2020Q1 phas Working Capital
WorkingCapital
65000000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2921000 USD
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1918000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1959000 USD
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2013000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
222131000 USD
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
230544000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
238000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
471000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
210000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
7925000 USD
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
238000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
471000 USD
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2638258 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5973505 shares
CY2019Q4 us-gaap Assets
Assets
82494000 USD
CY2020Q1 us-gaap Assets
Assets
76858000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
78823000 USD
CY2020Q1 us-gaap Assets Current
AssetsCurrent
72541000 USD
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
11000 USD
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1031000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74025000 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59441000 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59400000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61051000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51914000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74025000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59441000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9137000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14584000 USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28796371 shares
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28810607 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28766404 shares
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28780640 shares
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
29000 USD
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
29000 USD
CY2019Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
209000 USD
CY2020Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
31000 USD
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
54000 USD
CY2019Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 USD
CY2020Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3086000 USD
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1746000 USD
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
738000 USD
CY2019Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
225000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-712000 USD
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1533000 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-713000 USD
CY2019Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
437000 USD
CY2020Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-337000 USD
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
91000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9602000 USD
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
84000 USD
CY2020Q1 us-gaap Interest Payable Current
InterestPayableCurrent
84000 USD
CY2019Q1 us-gaap Interest Expense
InterestExpense
226000 USD
CY2020Q1 us-gaap Interest Expense
InterestExpense
378000 USD
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4000 USD
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2316000 USD
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3159000 USD
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
98000 USD
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
246000 USD
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
317000 USD
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
211000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2067000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
498000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
278000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
272000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
363000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
377000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
279000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
358000 USD
CY2010Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2019Q4 us-gaap Liabilities
Liabilities
22516000 USD
CY2020Q1 us-gaap Liabilities
Liabilities
23372000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82494000 USD
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
76858000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8479000 USD
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7495000 USD
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2378000 USD
CY2020Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
3686000 USD
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12326000 USD
CY2020Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11058000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-322000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9901000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-84000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-658000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8731000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23827000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-14905000 USD
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
8037000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7293000 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
14608000 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7384000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14288000 USD
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
100000 USD
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
100000 USD
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1709000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
265000 USD
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
271000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1508000 USD
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1438000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1715000 USD
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1648000 USD
CY2020Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.064
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10M25D
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
266000 USD
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
103000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
32000 USD
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
32000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
203000 USD
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
295000 USD
CY2019Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
CY2020Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
100000 USD
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
91000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-617000 USD
CY2019Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1233000 USD
CY2020Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
896000 USD
CY2019Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
129000 USD
CY2020Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
132000 USD
CY2019Q1 us-gaap Payments For Proceeds From Derivative Instrument Financing Activities
PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
0 USD
CY2020Q1 us-gaap Payments For Proceeds From Derivative Instrument Financing Activities
PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
-10000000 USD
CY2019Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2020Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
116000 USD
CY2019Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2020Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
100000 USD
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
84000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
558000 USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Units Offering Costs
PreferredUnitsOfferingCosts
200000000.0 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3565000 USD
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12204000 USD
CY2019Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
616000 USD
CY2020Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17000 USD
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-7293000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-14905000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3883000 USD
CY2020Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4650000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1924000 USD
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2637000 USD
CY2019Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
938000 USD
CY2020Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5721000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11449000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-162158000 USD
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-177100000 USD
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-177063000 USD
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
653000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
320000 USD
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
238000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
471000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
50927000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
44082000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
59978000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
53486000 USD
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
29967 shares
CY2020Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
29967 shares
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
24000 USD
CY2020Q1 us-gaap Treasury Stock Value
TreasuryStockValue
24000 USD
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24498388 shares
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28773274 shares
CY2020Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains certain deposit accounts and money market funds in federally insured financial institutions in excess of federally insured limits. The Company could experience losses on the money market funds in the future.</font></div></div>
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The preparation of the Company&#8217;s condensed financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s condensed financial statements and accompanying notes. The most significant estimates in the Company&#8217;s condensed financial statements relate to the valuation of the development derivative liability and the clinical trial accruals. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001169245-20-000051-index-headers.html Edgar Link pending
0001169245-20-000051-index.html Edgar Link pending
0001169245-20-000051.txt Edgar Link pending
0001169245-20-000051-xbrl.zip Edgar Link pending
a10-q2020q1.htm Edgar Link pending
ex-321xphas10xq2020q1.htm Edgar Link pending
ex-322xphas10xq2020q1.htm Edgar Link pending
ex311-phas10xq2020q1.htm Edgar Link pending
ex312-phas10xq2020q1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
phas-20200331.xml Edgar Link completed
phas-20200331.xsd Edgar Link pending
phas-20200331_cal.xml Edgar Link unprocessable
phas-20200331_def.xml Edgar Link unprocessable
phas-20200331_lab.xml Edgar Link unprocessable
phas-20200331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending